EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant unmet medical need for concussion treatment.